BioCryst Pharmaceuticals Statistics
Total Valuation
BCRX has a market cap or net worth of $1.50 billion. The enterprise value is $2.03 billion.
Important Dates
The next estimated earnings date is Monday, May 5, 2025, before market open.
| Earnings Date | May 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BCRX has 208.96 million shares outstanding. The number of shares has increased by 7.54% in one year.
| Current Share Class | 208.96M |
| Shares Outstanding | 208.96M |
| Shares Change (YoY) | +7.54% |
| Shares Change (QoQ) | +0.23% |
| Owned by Insiders (%) | 0.97% |
| Owned by Institutions (%) | 74.96% |
| Float | 195.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.31 |
| Forward PS | 2.62 |
| PB Ratio | -3.17 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.50 |
| EV / EBITDA | 1,170.95 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.63
| Current Ratio | 2.63 |
| Quick Ratio | 2.49 |
| Debt / Equity | n/a |
| Debt / EBITDA | 208.58 |
| Debt / FCF | n/a |
| Interest Coverage | -0.01 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -0.16% |
| Return on Invested Capital (ROIC) | -0.21% |
| Return on Capital Employed (ROCE) | -0.39% |
| Revenue Per Employee | $777,090 |
| Profits Per Employee | -$153,243 |
| Employee Count | 580 |
| Asset Turnover | 0.89 |
| Inventory Turnover | 10.11 |
Taxes
In the past 12 months, BCRX has paid $1.93 million in taxes.
| Income Tax | 1.93M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +53.96% in the last 52 weeks. The beta is 1.75, so BCRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.75 |
| 52-Week Price Change | +53.96% |
| 50-Day Moving Average | 7.95 |
| 200-Day Moving Average | 7.70 |
| Relative Strength Index (RSI) | 47.41 |
| Average Volume (20 Days) | 3,146,453 |
Short Selling Information
The latest short interest is 20.73 million, so 9.92% of the outstanding shares have been sold short.
| Short Interest | 20.73M |
| Short Previous Month | 19.77M |
| Short % of Shares Out | 9.92% |
| Short % of Float | 10.63% |
| Short Ratio (days to cover) | 5.78 |
Income Statement
In the last 12 months, BCRX had revenue of $450.71 million and -$88.88 million in losses. Loss per share was -$0.43.
| Revenue | 450.71M |
| Gross Profit | 264.79M |
| Operating Income | -1.28M |
| Pretax Income | -146.50M |
| Net Income | -88.88M |
| EBITDA | 1.73M |
| EBIT | -1.28M |
| Loss Per Share | -$0.43 |
Full Income StatementBalance Sheet
The company has $320.85 million in cash and $841.42 million in debt, giving a net cash position of -$520.57 million or -$2.49 per share.
| Cash & Cash Equivalents | 320.85M |
| Total Debt | 841.42M |
| Net Cash | -520.57M |
| Net Cash Per Share | -$2.49 |
| Equity (Book Value) | -475.93M |
| Book Value Per Share | -2.28 |
| Working Capital | 261.58M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$52.02 million and capital expenditures -$1.12 million, giving a free cash flow of -$53.14 million.
| Operating Cash Flow | -52.02M |
| Capital Expenditures | -1.12M |
| Free Cash Flow | -53.14M |
| FCF Per Share | -$0.25 |
Full Cash Flow StatementMargins
Gross margin is 58.75%, with operating and profit margins of -0.28% and -19.72%.
| Gross Margin | 58.75% |
| Operating Margin | -0.28% |
| Pretax Margin | -19.29% |
| Profit Margin | -19.72% |
| EBITDA Margin | 0.38% |
| EBIT Margin | -0.28% |
| FCF Margin | n/a |
Dividends & Yields
BCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.54% |
| Shareholder Yield | -7.54% |
| Earnings Yield | -5.89% |
| FCF Yield | -3.52% |
Dividend DetailsAnalyst Forecast
The average price target for BCRX is $15.67, which is 117.94% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.67 |
| Price Target Difference | 117.94% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 15.80% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BCRX has an Altman Z-Score of -2.66 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.66 |
| Piotroski F-Score | 4 |